Loading
Protagonist Therapeutics, Inc Stock: price and insider trades · United States
Protagonist Therapeutics, Inc: what insiders have been doing
Protagonist Therapeutics, Inc, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Protagonist Therapeutics, Inc logged 50 filings by 11 insiders.
No insider bought on the market over the period, while 3 insiders filed 15 sales totalling €44.1M. Patel Dinesh V Ph d filed the largest sale, €8.5M, on 12 August 2026, which represents 0.11% of the company's market value.
With 50 filings in twelve months, the company is more active than the median of 19 filings across the 5,814 companies we follow on the same exchange. Over the whole record (from 2021), the tally stands at no purchases and 34 sales. The 10-K for the year ended 31 December 2025 shows 46.0 m USD of revenue and -130.1 m USD of net income.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
135
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€54M
34 ops. · all time
Who traded when
BuySaleDinesh V. Ph D. Patel9 sales
Asif Ali8 sales
Arturo Md Molina5 sales
Waddill William D.3 sales
Analyst consensus: bullish or bearish?
Analysts rate Protagonist Therapeutics, Inc Strong Buy (bullish), based on 14 analysts. Average price target: US$178.21.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$136.28
Analyst consensus
14 analystsStrong buy
US$149.00Target US$178.21(+31%)US$225.00
Income statement
RevenueUS$46M
EBITDA-US$156.8M-341% margin
Net income-US$130.1M29.4% margin
Valuation
PER (trailing)134.9x
PER (forward)-922.3x
P/Book10.5x
Beta1.52
Balance sheet & cash
Market capUS$8.8B
Total debtUS$10.3M
Free Cash FlowUS$56.1M
Debt / Equity1%
Profitability & ownership
ROE11.0%
ROA4.5%
% insiders0.7%
% institutions119.7%
Last declaration on 2 October 2026
Declarations135 total
54,174 shares@ US$21.580.012% mcap2.2% of flowCommon StockSEC:0001104659-26-106831:0
54,174 shares@ US$145.870.084% mcap14.7% of flowCommon StockSEC:0001104659-26-106831:1
63,548 shares@ US$21.580.015% mcap2.5% of flowCommon StockSEC:0001104659-26-106831:2
63,548 shares@ US$146.180.099% mcap17.2% of flowCommon StockSEC:0001104659-26-106831:3
7,278 shares@ US$21.580.0017% mcap0.3% of flowCommon StockSEC:0001104659-26-106831:4
7,278 shares@ US$144.100.011% mcap1.9% of flowCommon StockSEC:0001104659-26-106831:5
510 shares0Common StockSEC:0001104659-26-105955:0
65,761 shares@ US$21.580.015% mcap2.6% of flowCommon StockSEC:0001104659-26-095111:0
34,239 shares@ US$21.580.0079% mcap1.4% of flowCommon StockSEC:0001104659-26-095111:2
34,239 shares@ US$148.520.055% mcap9.5% of flowCommon StockSEC:0001104659-26-095111:3
65,761 shares@ US$149.110.11% mcap18.3% of flowCommon StockSEC:0001104659-26-095111:1
225,000 shares@ US$149.260.37% mcap100.0% of flowCommonSEC144:0001968582-26-000805
9,000 shares@ US$115.0352.4% of flowCommonSEC144:0001950047-26-006422
9,000 shares@ US$105.8747.6% of flowCommonSEC144:0001950047-26-005894
75,000 shares@ US$21.580.016% mcap3.0% of flowCommon StockSEC:0001104659-26-061476:0
1,460 shares0Common StockSEC:0001104659-26-048572:0
15,000 shares@ US$8.043.8% of flowCommon StockSEC:0001104659-26-036319:0
25 of 135 declarations
About Protagonist Therapeutics, Inc
Protagonist Therapeutics, Inc. is a U.S.-listed biopharmaceutical company traded on the NASDAQ (NYSE/NASDAQ universe), headquartered in Newark, California, in Silicon Valley, United States. The company was built around a peptide-based discovery platform aimed at engineering structurally constrained therapeutic peptides that can preserve some of the selectivity and potency associated with biologics while offering a development profile that may be more practical than traditional antibody programs in certain settings. For equity investors, Protagonist is best viewed as a development-stage biotech: its valuation is driven primarily by clinical, regulatory, and partnering milestones rather than mature product revenue. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1377121/000110465926019696/ptgx-20251231x10k.htm?utm_source=openai))
Historically, Protagonist has focused on transforming its proprietary science into drug candidates against biologically validated targets. Its strategy combines internal R&D with selective partnerships, allowing the company to advance high-value assets while preserving optionality through licensing economics. The company also describes itself as having a global footprint, with operations in Newark and Brisbane, Australia, reflecting an execution model that is not purely domestic even though its corporate headquarters and stock market listing are in the United States. ([protagonist-inc.com](https://www.protagonist-inc.com/locations?utm_source=openai))
Read moreShow less
The core business lines are centered on immunology, inflammation, and selected hematology/metabolic opportunities. The most advanced program is rusfertide, a hepcidin functional mimetic being developed for polycythemia vera (PV). According to recent SEC filings and company updates, a New Drug Application was submitted in 2025 and the program was under priority review in 2026. Protagonist has also expanded its preclinical pipeline with PN-8047, an oral hepcidin mimetic, plus obesity assets such as PN-477 and PN-458, and an oral IL-4R alpha antagonist for atopic dermatitis and moderate-to-severe asthma. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1377121/000110465926055661/ptgx-20260331x10q.htm?utm_source=openai))
In competitive terms, Protagonist is not a large-scale commercial pharma company; rather, its competitive position depends on scientific differentiation, the novelty of its peptide platform, and the ability to convert pipeline progress into partnering value. That is why collaborations matter so much to the investment case. The company’s arrangements with Takeda and Johnson & Johnson provide access to potential milestones, royalties, and commercial economics while reducing some development risk. In 2026, the company disclosed a $50 million milestone related to FDA approval of icotytde, and it also exercised its right to opt out of the U.S. profit-and-loss sharing structure with Takeda for rusfertide, reshaping the future economics of that asset toward a royalty-based model. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1377121/000110465926055661/ptgx-20260331x10q.htm?utm_source=openai))
Recent news underscores a catalyst-rich profile. Protagonist reported full-year 2025 results in February 2026, followed by a first-quarter 2026 update in May 2026. Those releases highlighted continued investment in discovery and development, a larger preclinical pipeline, and ongoing regulatory progress on rusfertide. For investors in France, Belgium, and Switzerland, the key takeaway is that PTGX remains a classic NASDAQ biotech story: high scientific optionality, meaningful partnering validation, and substantial upside or downside tied to clinical readouts and FDA decisions in the United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001377121/000110465926055629/tm2613550d1_ex99-1.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
